Viking Therapeutics' shares tanked recently after its oral drug, VK2735, spooked investors with a high discontinuation rate. However, it achieved weight loss results similar to Eli Lilly's drug.
VK2735 shows strong early weight-loss data, positioning Viking as a potential third major player in the booming GLP-1 obesity drug market. Despite a sharp stock decline, Viking is well-funded, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results